Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios A Dimopoulos*, Evangelos Terpos, APOLLO Trial Investigators, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tahamtan Ahmadi, Jon Ukropec, Tobias Kampfenkel, Jordan M Schecter, Yanping QiuHimal Amin, Jessica Vermeulen, Robin Carson, Pieter Sonneveld

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

178 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology